Roivant Sciences Business Segments — Revenue increased by 26.1% to $2.52M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 66.7%, from $7.57M to $2.52M. Over 2 years (FY 2023 to FY 2025), Business Segments — Revenue shows a downward trend with a -49.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market demand or successful commercialization of the segment's offerings.
This represents the total gross income generated by a specific business segment from its primary commercial activities....
Standard across biopharma for tracking commercial product performance.
roiv_segment_reportable_segment_revenue| Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.18M | $8.18M | $8.18M | $8.18M | $7.99M | $4.48M | $9.02M | $7.57M | $2.17M | $1.57M | $2.00M | $2.52M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -2.3% | -44.0% | +101.5% | -16.1% | -71.3% | -27.6% | +27.2% | +26.1% |
| YoY Change | — | — | — | — | -2.3% | -45.3% | +10.3% | -7.4% | -72.8% | -64.9% | -77.8% | -66.7% |